Crescent Biopharma (CBIO) reported second-quarter 2026 financial results and recent business updates, including continued enrollment in its ASCEND Phase 1/2 trial of CR-001 across multiple solid tumor types.
The company reported a net loss of $24.8 million, or $0.74 per basic and diluted share, for the quarter ended June 30, 2026. Cash and cash equivalents were $171.6 million at quarter-end, and pro forma cash was $305.1 million after reflecting net proceeds from a July 2026 public offering.
- CR-001 enrollment is progressing in the global ASCEND Phase 1/2 clinical trial.
- Kelun-Biotech initiated a Phase 2 trial in China of CR-001 with sacituzumab tirumotecan in NSCLC.
- CR-003 Phase 1/2 testing is ongoing in China, with proof-of-concept data expected in Q1 2027.
- CR-002 remains on track to begin a global Phase 1/2 trial in the second half of 2026.
- Crescent completed a $143.7 million public offering in July 2026 and expects cash runway into the second half of 2028.
EARLY ACCESS
Receive GLYC Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
